T-cell Therapy Market Size, Share, Growth Analysis, By Modality(Research, Commercialized), By Type(CAR T-cell Therapy, T Cell Receptor (TCR)-based, Tumor Infiltrating Lymphocytes (TIL)-based), By Indication(Hematologic Malignancies, Solid Tumors, others), By End User(Hospitals, Specialty Clinics, Homecare, Others), By Region - Industry Forecast 2024-2031

T-cell Therapy Market size was valued at USD 7095.83 million in 2019 and is poised to grow from USD 8344.7 million in 2023 to USD 35898.15 million by 2031, growing at a CAGR of 17.6% in the forecast period (2024-2031).

T cell therapy Market is fragmented and competitive due to the presence of major players. Companies are clamouring to invest in the creation of innovative CAR T-cell treatment due to the exponential increase in the use of precision medicine on a worldwide scale. To maintain a competitive edge and increase their market position in the worldwide Tcell therapy market, leading companies are increasingly focusing on implementing tactics such as adopting new technology, product developments, mergers and acquisitions, joint venture, alliances, and partnerships. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Novartis AG', 'Merck KGaA', 'Gilead Sciences Inc.', 'Kite Pharma, Inc.', 'Juno Therapeutics Inc.', 'Pfizer Inc.', 'Celgene Corporation', 'bluebird bio, Inc.', 'Adaptimmune Therapeutics plc', 'Atara Biotherapeutics, Inc.', 'Mustang Bio, Inc.', 'TCR² Therapeutics Inc.', 'Autolus Therapeutics plc', 'Immunocore Limited', 'Eureka Therapeutics, Inc.', 'Ziopharm Oncology, Inc.', 'Precision Biosciences Inc.', 'Sorrento Therapeutics, Inc.', 'Fate Therapeutics, Inc.', 'Celyad Oncology SA', 'Caribou Biosciences, Inc.'

Following the FDA's approval of Yescarta, Kymriah, and Tecartus, a number of businesses have switched from developing protein- and small-molecule-based therapeutics to adoptive therapies as their primary business model. The market for T-cell treatment has grown as a result of strategic expenditures made in this area by both public and commercial organisations.

CAR T-cell therapies are being used in treatment of solid tumors. CAR T-cell treatment has demonstrated a considerable potential benefit in diffusing midline glioma, a deadly paediatric tumour that affects school-age children and young adults. A study using CAR T cells in animal models to promote prolonged eradication of diffuse midline glioma tumours produced encouraging findings, although some of the animals perished due to toxicity-related problems. For the therapy of brain tumours, intracerebroventricular (ICV) distribution of CAR T was much more effective and less toxic than systemic delivery was found later.

North America held the largest market share of T cell therapy Market in 2021 and accounted for the largest revenue share of around 41% in 2021. Strong research, a thriving industry, and a significant number of clinical trials for T-cell treatments being carried out in the U.S. have all significantly aided in the region's market supremacy. Additionally, the market has grown significantly as a result of the rising number of regulatory approvals in the U.S. and Canada as well as the region's shifting reimbursement environment. Additionally, the expansion of the regional market is aided by the large number of medical facilities that provide CAR-T cell therapy.